Clinical and prognostic significance of CD14 (+) HLA-DR (-/low) myeloid-derived suppressor cells in patients with hepatocellular carcinoma received transarterial radioembolization with Yttrium-90.

Autor: Boral B; Department of Immunology, Adana Health Practice and Research Center, University of Health Sciences, Adana, Turkey., Ballı HT; Department of Radiology, Çukurova University School of Medicine, Adana, Turkey., Sözütok S; Department of Radiology, Çukurova University School of Medicine, Adana, Turkey., Pehlivan UA; Department of Radiology, Çukurova University School of Medicine, Adana, Turkey., Aikimbaev K; Department of Radiology, Çukurova University School of Medicine, Adana, Turkey.
Jazyk: angličtina
Zdroj: Scandinavian journal of immunology [Scand J Immunol] 2022 Mar; Vol. 95 (3), pp. e13132. Date of Electronic Publication: 2021 Dec 30.
DOI: 10.1111/sji.13132
Abstrakt: Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. For unresectable HCC, transarterial radioembolization (TARE) with Yttrium-90 is a widely used treatment. The aim of this study was to investigate whether monocytic myeloid-derived suppressor cells (M-MDSC) and CD39+ T cells can be non-invasive predictive biomarkers of radiological response and prognosis in patients with HCC treated with TARE. This study was conducted on 39 patients with HCC who were treated with TARE between August 2018 and December 2019 and the control group consisted of 23 healthy volunteers. CD4+, CD8+, CD39+ T cells, Natural killer (NK) cells, myeloid cells (MC) and M-MDSC parameters are examined in the course of TARE treatment with student t test and Kaplan-Meier method. There were statistically significant differences in M-MDSC, CD39+ T cells and MC values between healthy controls and HCC patients. A statistically significant difference was found in M-MDSC and CD4+ T cells values in the HCC patient group who responded to the treatment compared to those who did not. Survival analysis found that patients with lower frequencies (under 3.81%) of M-MDSC showed more prominent differences of overall survival (OS) compared to patients with all high groups. We found that M-MDSC in the peripheral blood might be a useful non-invasive biomarker to predict OS. We have shown for the first time that M-MDSC is correlated with treatment response in HCC patients treated with TARE. Additionally, we have found that the percentage of CD39+ T cells is high in HCC patients and these cells are positively correlated with M-MDSC.
(© 2021 The Scandinavian Foundation for Immunology.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje